STOCK TITAN

Predictive Oncology Inc. - POAI STOCK NEWS

Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.

Predictive Oncology Inc. (NASDAQ: POAI) is at the forefront of using data and artificial intelligence (AI) to create personalized cancer treatments, aiming for more effective therapies and better patient outcomes. The company's mission revolves around precision medicine in cancer diagnosis, leveraging several key resources:

  • Database: A comprehensive database of clinically validated historical and outcome data from patient tumors.
  • CLIA-Certified Lab: An in-house Clinical Laboratory Improvement Amendments (CLIA) certified lab.
  • Smart Tumor Profiling: A patient-derived tumor profiling platform that offers intelligent insights.
  • Bioinformatics AI Platform: An advanced AI platform for in-house bioinformatics.
  • Innovative Tumor Growth: Techniques for growing tumors in the lab to rapidly develop patient-specific treatment options.
  • FDA-Approved System: The FDA-approved STREAMWAY System for automated medical fluid waste management.

Predictive Oncology's business is structured across three main segments:

  • Pittsburgh Segment: Focuses on AI applications using a proprietary biobank with over 150,000 tumor samples and creates 3D culture models for drug development.
  • Birmingham Segment: Provides contract research services targeting solubility improvements, stability studies, and protein production.
  • Eagan Segment: Produces the FDA-cleared STREAMWAY System for medical fluid disposal, driving the majority of the company's revenue.

Recent achievements highlight the company's collaborative efforts with pharmaceutical, diagnostic, and biotech industries:

  • Hosted an investor call and webcast on November 14th, providing insights into future strategies and financial performance.
  • Presented a study in collaboration with UPMC Magee-Womens Hospital, utilizing AI to predict ovarian cancer survival outcomes better than clinical data alone.
  • Announced a partnership with FluGen to develop a stable intranasal flu vaccine, leveraging Predictive Oncology’s biologics capabilities.
  • Unveiled a proprietary 3D cell culture model to enhance cancer drug discovery.
  • Introduced a new platform for functional and stable G-Protein Coupled Receptors (GPCRs), targeting advancements in cancer therapeutics.

Predictive Oncology's AI platform, PEDAL, has been validated to predict tumor sample responses to drug compounds with 92% accuracy. This platform, combined with the company's biobank of over 150,000 tumor samples and CLIA lab facilities, positions Predictive Oncology as a leader in AI-driven drug discovery and development.

Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) announced the reconvening of its virtual Special Meeting of Stockholders to December 30, 2020, at 3 p.m. CST. The company urges shareholders to vote 'FOR' the proposal to reincorporate in Nevada, which would eliminate an annual Delaware franchise tax of approximately $170,000, saving about $158,000 annually. The board believes Nevada's laws provide better protections for the company and its officers. The reincorporation requires majority approval from outstanding shares, as previous votes did not meet the threshold.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.61%
Tags
none
-
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) announced that its Special Meeting of Stockholders, originally scheduled for December 1, 2020, was adjourned due to lack of quorum. The meeting will reconvene on December 30, 2020, at 3 p.m. CST, via live audio webcast. Stockholders of record, dated as of October 28, 2020, are encouraged to vote by proxy to ensure their votes are counted. The company operates through three segments with a focus on applying artificial intelligence in drug discovery and personalized medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
Rhea-AI Summary

Predictive Oncology (POAI) reported its Q3 2020 financial results, maintaining revenues at $0.5 million, similar to the previous year. The company achieved a gross margin of 64%, up from 60%, attributed to reduced manufacturing costs. However, operating loss rose to $5.6 million, influenced by a $3.0 million non-cash goodwill impairment. The net loss increased to $6.9 million, or $(0.46) per share, compared to $(1.31) per share in 2019. Business highlights included signing a contract with a pharmaceutical company and licensing 71 unique ovarian cancer cell lines, bringing the total to 96.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz discussed the company's recent milestones and future goals in an interview with NetworkNewsWire. Key subsidiaries highlighted include TumorGenesis, which has developed a novel lab media to replace animal testing for tumors, and Soluble Biotech, which has expanded its research capabilities. Schwartz also emphasized Helomics' extensive tumor data, which positions it for competitive success in the market. The full interview provides further insights into these developments and the company's strategic direction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.99%
Tags
none
-
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) released a letter from CEO Carl Schwartz addressing shareholders amid a declining stock price. Despite this downturn, he assures investors of positive progress, highlighting stable cash burn and increasing revenue trends. The company’s divisions, including Skyline Medical and Helomics, are experiencing operational advancements, with new product launches and successful collaborations. Predictive Oncology is poised for growth, with solid cash reserves and strategic partnerships on the horizon, aiming for revenue generation by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
none
-
Rhea-AI Summary

TumorGenesis, a division of Predictive Oncology (NASDAQ: POAI), has acquired a license for 71 unique ovarian cancer cell lines, increasing its total to 96. This was done in collaboration with Ximbio, enhancing research capabilities in ovarian cancer. The new media developed for these cells retains over 95% of DNA and RNA, providing a robust tool for researchers. Richard Gabriel, President of TumorGenesis, emphasized that this advancement addresses the challenges presented by standard media mixes and aims to improve reproducibility in preclinical research, potentially saving the industry billions in research costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
none
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) announced its participation in the LD Micro's LD 500 Virtual Investor Conference, scheduled for September 2, 2020, at 3:40 PM ET. The event will provide an opportunity for company management to present and discuss its advancements in artificial intelligence applied to personalized medicine and drug discovery. A live webcast will be available to the public and archived for 90 days. For more details, visit the webcast link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
conferences
-
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) announced the sale of 8 STREAMWAY systems to a Virginia university hospital for a new surgical center, adding to the 2 systems already in use. This transaction is anticipated to yield approximately 4,000 procedures annually. In total, the company has sold 13 STREAMWAY systems in Q3 2020. The STREAMWAY System automates medical fluid disposal, showcasing POAI's advancements in personalized medicine and AI application in drug discovery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
-
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) announces that its chief innovation officer, Mark Collins, Ph.D., recently spoke on DojoLIVE!, discussing the potential of AI in cancer treatment. Helomics, a subsidiary, utilizes its Tumor Drug Response Profiling (TDRP) platform, which has generated profiles from over 150,000 tumors, aiming to personalize cancer therapies and collaborate with pharma on new therapies. The company also operates TumorGenesis and Skyline Medical. It's important to note the inherent risks in forward-looking statements as they may vary from actual results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
none
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) reported Q2 2020 financial results, highlighting a revenue of $183,000, down from $286,000 year-over-year. The company achieved its first commercial sale of ovarian cancer cell media and completed acquisitions of Soluble Therapeutics and BioDtech, enhancing its capabilities in precision medicine. The net loss was $3.6 million, with improvements in operational expenses. Management is optimistic about ongoing Helomics and TumorGenesis initiatives while raising $4.6 million through equity offerings to strengthen liquidity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags

FAQ

What is the current stock price of Predictive Oncology (POAI)?

The current stock price of Predictive Oncology (POAI) is $0.72 as of November 22, 2024.

What is the market cap of Predictive Oncology (POAI)?

The market cap of Predictive Oncology (POAI) is approximately 4.8M.

What does Predictive Oncology Inc. specialize in?

Predictive Oncology Inc. specializes in using data and AI to develop personalized cancer therapies, improving treatment effectiveness and patient outcomes.

What are the key segments of Predictive Oncology’s business?

The key segments are Pittsburgh (AI applications and biobank), Birmingham (contract research services), and Eagan (medical fluid disposal systems).

What recent collaborations has Predictive Oncology announced?

Recent collaborations include a study with UPMC Magee-Womens Hospital, and a partnership with FluGen for a stable intranasal flu vaccine.

How accurate is Predictive Oncology’s AI platform PEDAL?

PEDAL can predict with 92% accuracy if a tumor sample will respond to a specific drug compound.

What is the significance of Predictive Oncology’s 3D cell culture model?

The 3D cell culture model closely mimics human tissue, providing better predictions of clinical outcomes and optimizing drug candidate selection.

How does Predictive Oncology’s STREAMWAY System benefit the healthcare industry?

The STREAMWAY System offers automated medical fluid waste management, improving safety and efficiency in medical fluid disposal.

What are GPCRs and why are they important in cancer treatment?

GPCRs are cell surface receptors involved in cancer progression. Predictive Oncology’s new technology aims to enhance drug discovery targeting GPCRs.

What is Predictive Oncology’s biobank?

Predictive Oncology's biobank contains over 150,000 tumor samples, providing a robust resource for AI-driven drug discovery and development.

Where is Predictive Oncology headquartered?

Predictive Oncology is headquartered in Pittsburgh, PA.

Who can I contact for investor relations at Predictive Oncology?

For investor relations, contact Tim McCarthy at LifeSci Advisors, LLC via email at tim@lifesciadvisors.com.

Predictive Oncology Inc.

Nasdaq:POAI

POAI Rankings

POAI Stock Data

4.80M
6.52M
2.16%
4.01%
2.23%
Medical Instruments & Supplies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
PITTSBURGH